Share

January 2019; 6 (1) Clinical/Scientific NotesOpen Access

Case of alemtuzumab-related alopecia areata management in MS

Jillian K. Chan, Anthony L. Traboulsee, Ana-Luiza Sayao
First published October 19, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000516
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
610

Share

Article Information

vol. 6 no. 1 e516
DOI: 
https://doi.org/10.1212/NXI.0000000000000516
PubMed: 
30568994
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received June 22, 2018
  • Accepted in final form August 8, 2018
  • First Published October 19, 2018.
Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Jillian K. Chan, MD,
    2. Anthony L. Traboulsee, MD and
    3. Ana-Luiza Sayao, MD
  1. Jillian K. Chan, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker for the MS Society of Canada. Presented MS 101 Education Event in Nanaimo, BC, Canada and received travel reimbursement only.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I consulted for Roche one time.

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. I received a fellowship grant from Biogen for my first year, and I received a fellowship grant from the Canadian network of MS clinics for my second year.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Anthony L. Traboulsee, MD and
    3. Scientific Advisory Boards:

    1. 1. Sanofi Genzyme (commercial) 2. MS Society of Canada (non profit) 3. Canadian Institute for Health Research (non profit) 4. CADTH (non profit)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Sanofi Genzyme (commercial) 2. Biogen (commercial) 3. Teva (commercial) 4. Novartis (commercial) 5. Hoffman la Roche (commercial) 6. MS Society of Canada (non profit) 7. Consortium of MS Centers (non profit)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. A. Traboulsee reports receiving consulting fees from (1) Biogen (commercial) (2) Novartis (commercial) (3) Hoffman la Roche (commercial) (4) Sanofi Genzyme (commercial) (5) Teva Innovation (commercial) (6) Chugai (commercial)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. A Traboulsee has been a principal investigator on clinical trials funded by Hoffman la Roche, Chugai, Novartis, Biogen and Sanofi Genzyme.

    Research Support, Government Entities:

    1. (1) Canadian Institute for Health Research, Principal Investigator 2012-2018 (2) Multiple Sclerosis Society of Canada, Principal Investigator 2012-2018

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Ana-Luiza Sayao, MD
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker Honorarium from Merck-Serono

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Advisory board consultancy for Merck-Serono, Novartis, Biogen, Roche and Genzyme

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Medicine (Neurology), University of British Columbia, Vancouver, British Columbia, Canada.
  1. Correspondence
    Dr. Chan jillian.chan{at}ubc.ca
View Full Text

Article usage

Article usage: October 2018 to August 2023

AbstractFullPdfSource
Oct 2018010529Highwire
Nov 2018017720Highwire
Dec 2018022024Highwire
Jan 2019322539Highwire
Feb 2019422123Highwire
Mar 2019014625Highwire
Apr 20192599Highwire
May 201935815Highwire
Jun 201928712Highwire
Jul 20192709Highwire
Aug 2019210311Highwire
Sep 20192427Highwire
Oct 20190567Highwire
Nov 201904512Highwire
Dec 201913912Highwire
Jan 20202749Highwire
Feb 20200435Highwire
Mar 20202304Highwire
Apr 20200539Highwire
May 202006216Highwire
Jun 20201526Highwire
Jul 20200545Highwire
Aug 20201317Highwire
Sep 202015011Highwire
Oct 20201444Highwire
Nov 202011812Highwire
Dec 20203313Highwire
Jan 20211259Highwire
Feb 20211133Highwire
Mar 20212383Highwire
Apr 20214169Highwire
May 20210216Highwire
Jun 20210223Highwire
Jul 202114511Highwire
Aug 20212251Highwire
Sep 20212278Highwire
Oct 202103728Highwire
Nov 202102016Highwire
Dec 20210244Highwire
Jan 20221123Highwire
Feb 20222215Highwire
Mar 202242810Highwire
Apr 20220171Highwire
May 20221227Highwire
Jun 20221217Highwire
Jul 20220205Highwire
Aug 20221334Highwire
Sep 202202613Highwire
Oct 202213113Highwire
Nov 202225426Highwire
Dec 20221186Highwire
Jan 20230367Highwire
Feb 202302710Highwire
Mar 20230122Highwire
Apr 20230106Highwire
May 202311111Highwire
Jun 20230146Highwire
Jul 20230710Highwire
Aug 20231912Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles